Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBG166 in advanced hepatocellular carcinoma
NCT06461624Phase 1Recruiting
- Sponsor
- Zhejiang University
- Start
- Jul 2024
- Primary completion
- Jul 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CBG166 in hepatocellular carcinoma (HCC), sponsored by Zhejiang University. Primary endpoints: Dose Limiting Toxicity at 28 days, Adverse Events at 24 months and 1 more. Started Jul 2024; status: recruiting.
02
Drugs
CBG166
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06461624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06461624.